ArticleAnimal models and experimental medicine2026
Transcriptomic validation of a 7,12 Dimethylbenz(a)anthracene (DMBA)-induced leukemia rat model: Parallels with human leukemogenesis.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundExperimental animal models are essential for understanding the molecular mechanisms of human leukemia and testing potential therapies. Chemical induction using 7,12-dimethylbenz[a]anthracene (DMBA) has shown promise in recapitulating features of leukemogenesis in rodents, but its molecular fidelity to human disease remains underexplored. The aim of this study was to evaluate the transcriptomic landscape of a DMBA-induced leukemia rat model and assess its alignment with known gene expression signatures and oncogenic pathways in human leukemia.
methodsMale Wistar rats were treated with DMBA to induce leukemia. RNA was extracted from whole blood and subjected to RNA sequencing. Differentially expressed genes (DEG) were identified using RNA-seq by expectation-maximization and NOISeq. Functional enrichment analysis, Gene Ontology mapping, and protein interaction networks were analyzed via STRING. Prognostic relevance of key DEGs was explored using data from the Human Protein Atlas.
resultsThe DMBA-induced model showed significant upregulation of leukemia-associated genes, including FLT3, NRAS, KRAS, ABL1, BCR, and NPM1. The top 10 up- and downregulated genes were enriched in pathways related to cell fate, proliferation, apoptosis, and immune regulation. Particularly, genes such as MEIS2, CXCL9, and WIF1 were linked to hematopoietic dysregulation and poor prognosis in various cancers. Comparative analysis revealed strong transcriptomic overlap with human leukemia/carcinogenesis gene signatures, supporting the model's translational validity.
conclusionIn conclusion, the DMBA-induced leukemia rat model exhibits a transcriptomic profile that closely mirrors key oncogenic and prognostic features of human leukemia. This model holds significant promise for preclinical studies targeting leukemogenesis and therapeutic intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.